药名为唑来膦酸，该药在2002年被美国 FDA获准用于癌症病人恶性高血钙的治疗。
Under the name Zometa, the drug was approved by the U. S. Food and Drug Administration for cancer patients in 2002.
唑来膦酸，二钠盐，四水合物。
目的：观察唑来膦酸联合放疗治疗骨转移癌的疗效。
Objective:To evaluate the efficacy of zoledronic acid combined with radiotherapy for metastatic bone tumours.
结论：唑来膦酸注射液治疗溶骨性癌转移引起骨痛安全有效。
Conclusion: Zoledronic acid injection provided a therapeutic alternative in the pain relief for patients with metastatic bone cancer.
唑来膦酸还没有研究治疗重度肾功能损害，不建议在此设置。
Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting.
唑来膦酸注射也伴随着骨矿物质密度和骨新陈代谢标志物的显著改善。
Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers.
本研究探讨唑来膦酸治疗恶性肿瘤骨转移性疼痛的镇痛效果和不良反应。
This study is to investigate the effect and adverse effect of Zoledronic acid in the treatment of osseous metastases pain of malignant tumor.
近年来，随着多项临床试验的开展，唑来膦酸潜在的抗肿瘤作用也越来越受到关注。
Recently, as several zoledronic acid related clinical trials are carried out, the anti-tumor effect of zoledronic acid attracts people's attention.
然而，对于唑来膦酸与其他抗肿瘤治疗合用的最佳方案和剂量、持续时间还需要进一步的研究。
However, some important questions remain, including optimal dosing, initiation and duration of therapy, to be studied in further investigations.
目的：观察补元通络汤联用唑来膦酸注射液治疗肾虚痰瘀阻滞型肺癌骨转移的临床疗效并探讨其机理。
Objective: to investigate the hemostasis of Buyuan Tongluo Tang in treating kidney deficiency and blood stasis type bone metastasis from lung cancer and to explore its mechanism.
目的：观察补元通络汤联用唑来膦酸注射液治疗肾虚痰瘀阻滞型肺癌骨转移的临床疗效并探讨其机理。
Objective: to investigate the hemostasis of Buyuan Tongluo Tang in treating kidney deficiency and blood stasis type bone metastasis from lung cancer and to explore its mechanism.
应用推荐